WHO approves Covaxin for Emergency Use Listing

Nov. 3: In a major development, the Technical Advisory Group (TAG), which is an independent advisory committee of the World Health Organisation (WHO), has given approval to Emergency Use Listing (EUL) status for India’s COVID-19 vaccine Covaxin.

Taking to its twitter handle on Wdnesday, WHO wrote, “”WHO has granted emergency use listing (EUL) to #COVAXIN (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #COVID19.” Developed by Bharat Biotech, WHO is currently in the process of assessing the data of Covaxin’s clinical trials for use of EUL.

🆕 WHO has granted emergency use listing (EUL) to #COVAXIN® (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #COVID19. pic.twitter.com/dp2A1knGtT

— World Health Organization (WHO) (@WHO) November 3, 2021

The approval of Covaxin for emergency use listing will amount to recognition and help pave the way for people who have taken the dose to qualify for vaccine mandates in other countries. Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.  Covaxin is the seventh to win WHO backing following two mRNA shots by Pfizer/BioNTech and Moderna, adenovirus vector vaccines developed by AstraZeneca and Johnson & Johnson, and China’s inactivated vaccines from Sinovac Biotech and Sinopharm.